July 1, 2022
AstraZeneca Hong Kong Gains Footprint in Rare Diseases with Alexion
We are pleased to announce that, from July 1, 2022, AstraZeneca will expand its presence in the Hong Kong market by adding Rare Diseases Therapies to its existing portfolio, following the acquisition of Alexion on 21 July 2021.
AstraZeneca is expanding Alexion’s reach to patients and growth potential by leveraging AZ subsidiaries through partnerships. As we are transitioning from partners, we are introducing Alexion/AstraZeneca, bringing new hope to the patients with rare diseases locally and globally. DKSH Hong Kong Limited is appointed as the service provider for handling the distribution service and AstraZeneca will handle the sales and marketing activities of rare disease products, with effect from 1 July, 2022.
There are over 7,000 known rare diseases that affect approximately 400 million people worldwide. People living with a rare disease represent one of the largest underserved patient communities in the world. Carol Mui, General Manager of AstraZeneca Hong Kong and Macau said: “Today marks a new chapter of AstraZeneca Hong Kong! It is truly a time of unprecedented opportunity for all of us to expand our ability to serve and positively impact patients in Hong Kong and Macau.”
Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong, expressed confidence in the new partnership, “AstraZeneca’s purpose to deliver life-changing and innovative science-driven medicine, guided with patient-focus, complements DKSH’s mission of enriching people’s lives. Through our expertise and experience, stringent quality control, and capillary and agile supply chain network for life-saving drugs, we stamped our support to AstraZeneca’s distribution with guaranteed reliability.”
Alexion/AstraZeneca share the same dedication to science and innovation to deliver life-changing medicines. The combined company will also have an enhanced global footprint and broad coverage across primary, speciality and highly specialised care.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on Twitter @AstraZeneca.
DKSH Hong Kong limited
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec
AstraZeneca is expanding Alexion’s reach to patients and growth potential by leveraging AZ subsidiaries through partnerships. As we are transitioning from partners, we are introducing Alexion/AstraZeneca, bringing new hope to the patients with rare diseases locally and globally. DKSH Hong Kong Limited is appointed as the service provider for handling the distribution service and AstraZeneca will handle the sales and marketing activities of rare disease products, with effect from 1 July, 2022.
There are over 7,000 known rare diseases that affect approximately 400 million people worldwide. People living with a rare disease represent one of the largest underserved patient communities in the world. Carol Mui, General Manager of AstraZeneca Hong Kong and Macau said: “Today marks a new chapter of AstraZeneca Hong Kong! It is truly a time of unprecedented opportunity for all of us to expand our ability to serve and positively impact patients in Hong Kong and Macau.”
Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong, expressed confidence in the new partnership, “AstraZeneca’s purpose to deliver life-changing and innovative science-driven medicine, guided with patient-focus, complements DKSH’s mission of enriching people’s lives. Through our expertise and experience, stringent quality control, and capillary and agile supply chain network for life-saving drugs, we stamped our support to AstraZeneca’s distribution with guaranteed reliability.”
Alexion/AstraZeneca share the same dedication to science and innovation to deliver life-changing medicines. The combined company will also have an enhanced global footprint and broad coverage across primary, speciality and highly specialised care.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on Twitter @AstraZeneca.
DKSH Hong Kong limited
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 33,100 specialists, generating net sales of CHF 11.1 billion in 2021. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,290 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2021. www.dksh.com/hec